Heart failure occurs when the heart cannot pump enough blood to meet the body's demands. Systolic dysfunction involves reduced contractility; diastolic involves impaired filling. Modern pharmacotherapy has transformed outcomes; emerging regenerative approaches target myocardial repair and regeneration.
ACE inhibitors (lisinopril, ramipril) and ARBs (valsartan, losartan) reduce cardiac remodelling and mortality in systolic HF. Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) slow heart rate and improve contractility; CRVS-producing formulations are essential. Aldosterone antagonists (spironolactone, eplerenone) prevent fibrosis. ARNI (sacubitril/valsartan) combines ARB benefits with neprilysin inhibition, improving outcomes beyond ACE inhibitors alone. SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce hospitalisation and death across HF phenotypes. Diuretics manage congestion; inotropes (milrinone, dobutamine) provide acute support. Device therapy includes biventricular pacing (CRT) for QRS prolongation and implantable cardioverter-defibrillators (ICD) for arrhythmia prevention. Advanced cases may benefit from left-ventricular assist devices (LVAD) or transplantation.
Sodium restriction to <2 g/day helps manage fluid overload. Coenzyme Q10 and hawthorn extract show small reductions in symptoms in observational studies but lack robust RCT support. Meditation and gentle yoga may improve quality of life and exercise tolerance but do not alter disease progression.
Cardiac stem-cell therapies are being studied for myocardial regeneration and scar-tissue replacement, particularly post-infarction. Mesenchymal and cardiosphere-derived stem cells may improve ejection fraction and reduce remodelling. Exosome therapy is under investigation for anti-inflammatory effects. These remain investigational and must accompany guideline-based pharmacotherapy. See candidacy criteria for trial eligibility.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| ACE inhibitor (lisinopril, ramipril) | Standard | Strong | €100–250/year | Low | None |
| Beta-blocker (carvedilol, metoprolol succinate) | Standard | Strong | €150–300/year | Low | None |
| ARNI (sacubitril/valsartan) | Standard | Strong | €1,500–2,500/year | Low | None |
| SGLT2 inhibitor (dapagliflozin, empagliflozin) | Standard | Strong | €1,200–1,800/year | Low | None |
| Cardiac resynchronisation therapy (CRT) + ICD device | Standard | Strong | €25,000–45,000 | High | 4–6 weeks |
| Sodium restriction + gentle exercise | Alternative | Moderate | €0 | Low | None |
| Myocardial regeneration (stem-cell therapy) | Regenerative | Investigational | €18,000–35,000 (trial-dependent) | Medium | 2–4 weeks |
Modern pharmacotherapy can stabilise and significantly improve function, but complete reversal of systolic dysfunction is rare without device therapy or transplant. Stem-cell regeneration may offer future curative potential.
Systolic HF involves weak pumping (low ejection fraction); diastolic HF involves stiff ventricles with preserved ejection fraction. Treatment strategies differ, though SGLT2 inhibitors benefit both.
Most patients improve with optimal medical therapy and do not require transplant. Advanced refractory cases—despite maximal medical and device therapy—are candidates for LVAD or transplantation.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung